Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT03088540

PHASE3

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Regeneron Pharmaceuticals

View on ClinicalTrials.gov

Summary

The primary objectives of the study are: * To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells * To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies

Official title: A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

712

Start Date

2017-05-29

Completion Date

2025-04-18

Last Updated

2026-06-25

Healthy Volunteers

Conditions

Carcinoma，Non-Small-Cell Lung Lung Carcinomas, Non-Small-Cell Non-small-cell Lung Carcinoma Nonsmall Cell Lung Cancer

Interventions

DRUG

Pemetrexed

Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin

DRUG

Paclitaxel

Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin

DRUG

Gemcitabine

Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin

DRUG

Cisplatin

Administered with either Pemetrexed, Paclitaxel or gemcitabine.

DRUG

Carboplatin

Administered with either Pemetrexed, Paclitaxel or gemcitabine.

DRUG

cemiplimab

Patients will be administered cemiplimab as per protocol.

Key Inclusion Criteria: A patient must meet the following criteria to be eligible for inclusion in the study: 1. Patients with histologically or cytologically documented squamous or non squamous NSCLC with stage IIIB or stage IIIC disease who are not candidates for treatment with definitive concurrent chemoradiation or patients with stage IV disease who received no prior systemic treatment for recurrent or metastatic NSCLC 2. Archival or newly obtained formalin-fixed tumor tissue from a metastatic/recurrent site, which has not previously been irradiated 3. Tumor cells expressing PD L1 above a specific percentage of tumor cells by IHC performed by the central laboratory 4. At least 1 radiographically measureable lesion per RECIST 1.1 5. ECOG performance status of ≤1 6. Anticipated life expectancy of at least 3 months 7. Adequate organ and bone marrow function Key Exclusion Criteria: A patient who meets any of the following criteria will be excluded from the study: 1. Patients that have never smoked, defined as smoking \<100 cigarettes in a lifetime 2. Active or untreated brain metastases or spinal cord compression 3. Patients with tumors tested positive for EGFR gene mutations, ALK gene translocations, or ROS1 fusions 4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to randomization 5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to randomization 6. Patients with active, known, or suspected autoimmune disease that has required systemic therapy in the past 2 years 7. Patients with a condition requiring corticosteroid therapy (\>10 mg prednisone/day or equivalent) within 14 days of randomization 8. Another malignancy that is progressing or requires treatment 9. Uncontrolled infection with hepatitis B or hepatitis C or human immunodeficiency virus (HIV) or diagnosis of immunodeficiency 10. Active infection requiring systemic therapy within 14 days prior to randomization 11. Prior therapy with anti-PD 1 or anti-PD L1 12. Treatment-related immune-mediated AEs from immune-modulatory agents 13. Receipt of an investigational drug or device within 30 days 14. Receipt of a live vaccine within 30 days of planned start of study medication 15. Major surgery or significant traumatic injury within 4 weeks prior to first dose 16. Documented allergic or acute hypersensitivity reaction attributed to antibody treatments 17. Known psychiatric or substance abuse disorder that would interfere with participation with the requirements of the study, including current use of any illicit drugs 18. Pregnant or breastfeeding women 19. Women of childbearing potential or men who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose Note: Other protocol defined Inclusion/Exclusion criteria apply.

Locations (192)

Clinical Study Site

Albury, New South Wales, Australia

Clinical Study Site

Wollongong, New South Wales, Australia

Clinical Study Site

Fitzroy, Australia

Clinical Study Site

Minsk, Belarus

Clinical Study Site

Mogilev, Belarus

Clinical Study Site 1

Porto Alegre, Rio Grande do Sul, Brazil

Clinical Study Site

Barretos, Brazil

Clinical Study Site

Curitiba, Brazil

Clinical Study Site

Joinville, Brazil

Clinical Study Site

Lajeado, Brazil

Clinical Study Site

Mogi das Cruzes, Brazil

Clinical Study Site

Passo Fundo, Brazil

Clinical Study Site

Pelotas, Brazil

Clinical Study Site 2

Porto Alegre, Brazil

Clinical Study Site 3

Porto Alegre, Brazil

Clinical Study Site

Recife, Brazil

Clinical Study Site

Rio de Janeiro, Brazil

Clinical Study Site

Salvador, Brazil

Clinical Study Site

Santa Cecília, Brazil

Clinical Study Site

São José do Rio Preto, Brazil

Clinical Study Site #3

São Paulo, Brazil

Clinical Study Site #4

São Paulo, Brazil

Clinical Study Site 1

São Paulo, Brazil

Clinical Study Site 2

São Paulo, Brazil

Clinical Study Site

Dobrich, Bulgaria

Clinical Study Site

Gabrovo, Bulgaria

Clinical Study Site

Recoleta, Chile

Clinical Study Site

Santiago, Chile

Clinical Study Site

Temuco, Chile

Clincial Study Site

Viña del Mar, Chile

Clinical Study Site

Lanshan, Shandong, China

Clinical Study Site

Guangdong, China

Clinical Study Site

Harbin, China

Clinical Study Site

Linyi, China

Clinical Study Site 1

Shanghai, China

Clinical Study Site 2

Shanghai, China

Clinical Study Site 1

Tianjin, China

Clinical Study Site 2

Tianjin, China

Clinical Study Site

Xuzhou, China

Clinical Study Site

Zhejiang, China

Clinical Study Site

Barranquilla, Colombia

Clinical Study Site

Bogotá, Colombia

Clinical Study Site

Floridablanca, Colombia

Clinical Study Site

Nový Jičín, Czechia

Clinical Study Site

Pelhřimov, Czechia

Clinical Study Site

Prague, Czechia

Clinical Study Site

Batumi, Georgia

Clinical Study Site #6

Tbilisi, Georgia

Clinical Study Site 1

Tbilisi, Georgia

Clinical Study Site 2

Tbilisi, Georgia

Clinical Study Site 3

Tbilisi, Georgia

Clinical Study Site 4

Tbilisi, Georgia

Clinical Study Site 5

Tbilisi, Georgia

Clinical Study Site

Pátrai, Achaia, Greece

Clinical Study Site

Cholargós, Attica, Greece

Clinical Study Site 1

Athens, Greece

Clinical Study Site 2

Athens, Greece

Clinical Study Site 3

Athens, Greece

Clinical Study Site

Larissa, Greece

Clinical Study Site

Pylaia, Greece

Clinical Study Site 1

Thessaloniki, Greece

Clinical Study Site 2

Thessaloniki, Greece

Clinical Study Site 3

Thessaloniki, Greece

Clinical Study Site

Gyula, Bekes County, Hungary

Clinical Study Site

Tatabánya, Komárom-Esztergom, Hungary

Clinical Study Site

Farkasgyepű, Veszprém megye, Hungary

Clinical Study Site

Budapest, Hungary

Clinical Study Site

Debrecen, Hungary

Clinical Study Site

Zalaegerszeg, Hungary

Clinical Study Site

Amman, Jordan

Clinical Study Site

Irbid, Jordan

Clinical Study Site

Bsalîm, Lebanon

Clinical Study Site

Mazraat ech Choûf, Lebanon

Clinical Study Site

Sidon, Lebanon

Clinical Study Site

Kampung Baharu Nilai, Malaysia

Clinical Study Site #1

Kuala Lumpur, Malaysia

Clinical Study Site #2

Kuala Lumpur, Malaysia

Clinical Study Site

Kuching, Malaysia

Clinical Study Site

Pulau Pinang, Malaysia

Clinical Study Site

Tanjong Bungah, Malaysia

Clinical Study Site

Coahuila, Mexico

Clinical Study Site

Cuautitlán, Mexico

Clinical Study Site

Jalisco, Mexico

Clinical Study Site

León, Mexico

Clinical Study Site 1

Monterrey, Mexico

Clinical Study Site 2

Monterrey, Mexico

Clinical Study Site 3

Monterrey, Mexico

Clinical Study Site

Oaxaca City, Mexico

Clinical Study Site

San Luis Potosí City, Mexico

Clinical Study Site

Bacolod City, Philippines

Clinical Study Site

Batangas, Philippines

Clinical Study Site

Cebu, Philippines

Clinical Study Site

City of Taguig, Philippines

Clinical Study Site

Davao City, Philippines

Clinical Study Site 1

Manila, Philippines

Clinical Study Site 2

Manila, Philippines

Clinical Study Site #1

Quezon City, Philippines

Clinical Study Site #2

Quezon City, Philippines

Clinical Study Site

Dąbrowa Górnicza, Poland

Clinical Study Site

Gdynia, Poland

And 92 more locations on ClinicalTrials.gov

Clinical Research Directory

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (192)